Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

van Rhee, F; Wong, R; Munshi, N; Rossi, J; Ke, X; Fosså, A; Simpson, D; Capra, M; Liu, T; Hsieh, R; Goh, Y; Zhu, J; Cho, S; Ren, H; Cavet, James; Bandekar, R; Rothman, M; Puchalski, T; Reddy, M; van de Velde, H; Vermeulen, J; Casper, C

Affiliation

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Issue Date

2014-08

Metadata

Show full item record

Abstract

Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease.

Citation

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. 2014, 15 (9):966-74 Lancet Oncol

Journal

The Lancet Oncology

URI

http://hdl.handle.net/10541/325867

DOI

10.1016/S1470-2045(14)70319-5

PubMed ID

25042199

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications